Biomea Fusion Reports Week 4 top-line results from GLP-131 study
The company provided early interim results from its Phase 1 clinical study of BMF-650, an investigational drug candidate designed to modulate the NLRP3-containing NLRP3 inflammasome.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed